DreamCIS

DreamCIS EBITDA per Share

The EBITDA per Share of DreamCIS (223250.KQ) as of Oct 29, 2026 is 220.08 KRW. In the previous year, EBITDA per Share was 262.65 KRW — a change of -16.21% (lower).

EBITDA per Share

220.08KRW

YoY

-16.21%

Last updated:

EBITDA per Share of DreamCIS is 2025 220.08 KRW. EBITDA per Share of DreamCIS was 2024 262.65 KRW. It decreases by -16.21% lower compared to the previous year.

The DreamCIS EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
904.66 KRW
Jan 1, 2019
1,117.54 KRW
Jan 1, 2020
898.84 KRW
Jan 1, 2021
175.11 KRW
Jan 1, 2022
288.73 KRW
Jan 1, 2023
114.87 KRW
Jan 1, 2024
262.65 KRW
Jan 1, 2025
220.08 KRW
The DreamCIS EBITDA per Share history
YEAREBITDA per ShareYoY
220.08KRW-16.21%
262.65KRW+128.66%
114.87KRW-60.22%
288.73KRW+64.88%
175.11KRW-80.52%
898.84KRW-19.57%
1,117.54KRW+23.53%
904.66KRW-467.08%
-246.45KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DreamCIS Stock analysis

What does DreamCIS do? DreamCIS Inc. is a company based in Seoul, South Korea, operating within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company went public on May 22, 2020, with its stock listed under the ticker 223250.KQ and ISIN KR7223250002. DreamCIS Inc. provides clinical online information and consultation services, focusing on regulatory post-marketing surveillance (rPMS), clinical trials, and non-interventional studies (NIS). The company serves both domestic and international markets, offering its services to clients seeking support in clinical research and regulatory compliance. Its headquarters are located in Seoul, South Korea. The company's website is http://www.dreamcis.com/, which serves as a primary source for further information about its services and operations. DreamCIS Inc. does not provide detailed information about its founding year, specific leadership, or financial figures beyond its IPO date, and no acquisitions or additional product names are mentioned in the provided data. The company's services are primarily aimed at facilitating clinical research and ensuring adherence to regulatory standards in the life sciences sector. DreamCIS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DreamCIS stock

EBITDA per Share of DreamCIS is 220.08 KRW in 2025.

EBITDA per Share of DreamCIS changed from 262.65 KRW to 220.08 KRW, representing a -16.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share DreamCIS since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — DreamCIS

All Key Metrics — DreamCIS